| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Departments of Gastrointestinal Medical Oncology [R. L., J. L. A.], Bioimmunotherapy [M. R.], Gynecologic Medical Therapeutics [C. V., A. P. K., J. J. K.], Diagnostic Radiology [M. E. H.], and Pathology [E. A. L.], Memorial Hermann Hospital, Houston, Texas; Departments of Gynecologic Oncology [M. A. N., M. E. G., R. S. F.] and Biomathematics [L. B. L.], The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030; and Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania [C. D. P.]
Purpose: The purpose is to determine dose-limiting toxicity, pharmacokinetics,pharmacodynamics, and immunobiology after i.p. injections of recombinant human IL-12 (rhIL-12).
Experimental Design: rhIL-12 was administered to 29 previously treated patients with peritoneal carcinomatosis from Müllerian carcinomas, gastrointestinal tract carcinomas and peritoneal mesothelioma in a Phase I trial. rhIL-12 doses were increased from 3 to 600 ng/kg. Three or more patients at each level received weekly i.p. injections of rhIL-12.
Results: Dose-limiting toxicity (elevated transaminase) occurred in 2 of 4 patients at the 600 ng/kg dose. More frequent toxicities included fever, fatigue, abdominal pain, nausea, and catheter-related infections. Ten patients received 300 ng/kg with acceptable frequency and severity of side effects. Two patients (one with ovarian cancer and one with mesothelioma) had no remaining disease at laparoscopy. Eight patients had stable disease and 19 progressive disease. At 300 ng/kg i.p., IL-12 was cleared from peritoneal fluid in a biphasic manner with a terminal-phase half-life of 18.7 h; peritoneal fluid levels of IL-12 5 min after i.p. injection were 100–200 pg/ml, and serum levels reached 
10 pg/ml between 24 and 36 h. IL-1-
, IL-2, IL-10, tumor necrosis factor , and IFN-
were determined in serum and peritoneal fluid. IFN-, IL-10, and tumor necrosis factor were detected most frequently. Immunobiological effects included peritoneal tumor cell apoptosis, decreased tumor cell expression of basic fibroblast growth factor and vascular endothelial growth factor, elevated IFN- and IFN-inducible protein 10 transcripts in peritoneal exudate cells, and increased proportions of peritoneal CD3+ relative to CD14+ cells.
Conclusions: rhIL-12 at 300 ng/kg by weekly i.p. injection is biologically active and adequately tolerated for Phase II studies.
This article has been cited by other articles:
|
|
 |
|
  M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini Interleukin-12: Biological Properties and Clinical Application Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Little, J. M. Pluda, K. M. Wyvill, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. Yarchoan Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma Blood, June 15, 2006; 107(12): 4650 - 4657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Verri Jr., R. O. Molina, I. R. S. Schivo, T. M. Cunha, C. A. Parada, S. Poole, S. H. Ferreira, and F. Q. Cunha Nociceptive Effect of Subcutaneously Injected Interleukin-12 Is Mediated by Endothelin (ET) Acting on ETB Receptors in Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Trudeau, M. M. Cotreau, L. Stonis, K. H. Dykstra, J. L. Oestreicher, A. Strahs, A. J. Dorner, V. H. Van Cleave, W. L. Trepicchio, and U. S. Schwertschlag A Single Administration of Recombinant Human Interleukin-12 Is Associated With Increased Expression Levels of Interferon-gamma and Signal Transducer and Activator of Transcription in Healthy Subjects J. Clin. Pharmacol., June 1, 2005; 45(6): 649 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al. Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease Clin. Cancer Res., August 15, 2004; 10(16): 5432 - 5438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. De Giovanni, G. Nicoletti, L. Landuzzi, A. Astolfi, S. Croci, A. Comes, S. Ferrini, R. Meazza, M. Iezzi, E. Di Carlo, et al. Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine Cancer Res., June 1, 2004; 64(11): 4001 - 4009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Feldman, S. K. Libutti, J. F. Pingpank, D. L. Bartlett, T. H. Beresnev, S. M. Mavroukakis, S. M. Steinberg, D. J. Liewehr, D. E. Kleiner, and H. R. Alexander Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy J. Clin. Oncol., December 15, 2003; 21(24): 4560 - 4567. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
